IRCT20091114002709N61尚未招募3 期
The effects of resveratrol supplement on some mediator genes of immunity and inflammation, inflammatory factors, oxidative stress and clinical outcomes in hospitalized acute ischemic stroke patients with enteral feeding in intensive care unit: A randomized triple-blind placebo-controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 85 years（—）
- 性别
- All
入选标准
- •Willingness to cooperate and complete the informed consent form by the patient or legal guardian, patients aged 18-85 years, body mass index = 35 kg/m2, starting the intervention within 24 hours after being admitted to the ICU and not spending More than 24 hours from the time of disease diagnosis until the time of entering the study, the severity of stroke based on the NIHSS standard is higher than 4, the patient's GCS at the time of visit is higher than 3, feeding by enteral feeding method, receiving at least 80 percent of the prescribed formula during the first 48 hours, none Absolute contraindications for enteral feeding (permanent ileus, ischemia of the digestive tract, bilious or continuous vomiting and mechanical obstruction), the possibility of hospitalization in the intensive care unit (ICU) for 30 days, not suffering from hepatic encephalopathy and liver cirrhosis, not suffering from metastatic cancer, not having infection and sepsis, not having AIDS (HIV), not having hepatitis, not receiving supplements or formulas that strengthen the immune system, including arginine, glutamine, colostrum, vitamins C and E, selenium, zinc or Omega-3 fatty acids or resveratrol supplement during the last 30 days before the start of the intervention, not suffering from allergies or intolerance to the enteral formula used in the present study and resveratrol supplement, non-participation in other interventional studies. No company in the past 30 days in other clinical trial studies at the same time as the present study
排除标准
- •Pregnancy, lactation, intracranial hemorrhage, history of previous stroke, consumption of any natural food containing resveratrol within 48 hours before the onset of stroke, patients who received rtPA, more than 24 hours from onset of symptoms, seizure at onset Stroke, intracranial hemorrhage, symptoms suggestive of subarachnoid hemorrhage, rapid recovery or partial symptoms, stroke severity based on NIHSS criteria less than 4, patient suffering from dementia before stroke
研究者
相似试验
招募中
3 期
Resveratrol in multiple sclerosisMultiple sclerosisMultiple Sclerosis.IRCT20230315057731N1Ahvaz University of Medical Sciences60
招募中
3 期
The effect of resveratrol on strokeIschemic stroke.Other cerebrovascular diseasesIRCT20191020045162N1Kermanshah University of Medical Sciences60
已完成
2 期
Evaluation of the effects of Resveratrol Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid profile, blood glucose, Insulin Sensitivity, and Hepatic fibrosis in patients with Nonalcoholic Fatty Liver Disease.on Alcoholic Fatty Liver.Inflammatory liver disease, unspecifiedIRCT201202014010N7ational Nutrition and Food Technology Research Institute50
已完成
3 期
Investigating the effect of resveratrol on polycystic ovary syndromePolycystic ovary syndrome.Polycystic ovary syndromeE28.2IRCT20221106056417N1Tehran University of Medical Sciences56
招募中
3 期
Resveratrol in COVID19IRCT20200112046089N1Ahvaz University of Medical Sciences50